Abstract
The Na+/H+ exchanger isoform 1 (NHE1) is a ubiquitously expressed transporter fulfilling a variety of cell physiological tasks. By importing Na+ and exporting H+, NHE1 contributes to regulatory volume increase and cytoplasmic pH homeostasis. In addition it anchors the cytoskeleton in the plasma membrane. NHE1 plays a critical role in mediating the progression of reperfusion injuries after ischemia. Moreover, it is upregulated and/or overexpressed in a number of tumour cells. In many cases an elevated NHE1 activity can be correlated with an increase in cell motility and malignancy. Consequently, NHE1 including its regulators may represent potential targets in anticancer therapy. Different NHE1 inhibitors are compared and possible clinical exploitations of NHE1 inhibition are discussed.
Keywords: Cancer treatment, cariporide (HOE642), growth factors, Na+/H+ exchanger, NHE1, pH, tumour microenvironment, physiological tasks, cytoplasmic pH homeostasis, plasma membrane, malignancy
Current Medicinal Chemistry
Title: Is the Multifunctional Na+/H+ Exchanger Isoform 1 a Potential Therapeutic Target in Cancer?
Volume: 19 Issue: 5
Author(s): C. Stock, F.T. Ludwig and A. Schwab
Affiliation:
Keywords: Cancer treatment, cariporide (HOE642), growth factors, Na+/H+ exchanger, NHE1, pH, tumour microenvironment, physiological tasks, cytoplasmic pH homeostasis, plasma membrane, malignancy
Abstract: The Na+/H+ exchanger isoform 1 (NHE1) is a ubiquitously expressed transporter fulfilling a variety of cell physiological tasks. By importing Na+ and exporting H+, NHE1 contributes to regulatory volume increase and cytoplasmic pH homeostasis. In addition it anchors the cytoskeleton in the plasma membrane. NHE1 plays a critical role in mediating the progression of reperfusion injuries after ischemia. Moreover, it is upregulated and/or overexpressed in a number of tumour cells. In many cases an elevated NHE1 activity can be correlated with an increase in cell motility and malignancy. Consequently, NHE1 including its regulators may represent potential targets in anticancer therapy. Different NHE1 inhibitors are compared and possible clinical exploitations of NHE1 inhibition are discussed.
Export Options
About this article
Cite this article as:
Stock C., Ludwig F.T. and Schwab A., Is the Multifunctional Na+/H+ Exchanger Isoform 1 a Potential Therapeutic Target in Cancer?, Current Medicinal Chemistry 2012; 19 (5) . https://dx.doi.org/10.2174/092986712798992101
DOI https://dx.doi.org/10.2174/092986712798992101 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antioxidant Therapy in Alzheimers Disease: Theory and Practice
Mini-Reviews in Medicinal Chemistry Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Stem Cells Derived from Human Exfoliated Deciduous Teeth (SHED) in Neuronal Disorders: A Review
Current Stem Cell Research & Therapy Effects of Dietary Polyunsaturated Fatty Acids on Mitochondria
Current Pharmaceutical Design Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Inhibition of IκB Phosphorylation by a Novel IKK Inhibitor IMD-1041 Attenuates Myocardial Dysfunction After Infarction
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Molecular Signals Elicited by GPCR Agonists in Hypertension, Cardiovascular Remodeling: Are MMPs and ADAMs Elusive Therapeutic Targets?
Current Hypertension Reviews Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research Aging is Neuroprotective During Global Ischemia but Leads to Increased Caspase-3 and Apoptotic Activity in Hippocampal Neurons
Current Neurovascular Research Psychiatric Disorders and TRP Channels: Focus on Psychotropic Drugs
Current Neuropharmacology Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology The Role of Venous Abnormalities in Neurological Disease
Reviews on Recent Clinical Trials Polyphenols: Well Beyond The Antioxidant Capacity: Polyphenol Supplementation and Exercise-Induced Oxidative Stress and Inflammation
Current Pharmaceutical Biotechnology Intravenous Antihypertensives within Cardiovascular-Based Continuity of Care
Current Vascular Pharmacology Ca2+ Signalling in Damaged Endothelium and Arterial Remodelling: Do Connexin Hemichannels Provide a Suitable Target to Prevent In-stent Restenosis?
Current Drug Therapy Redox State, Oxidative Stress, and Molecular Mechanisms of Protective and Toxic Effects of Bilirubin on Cells
Current Pharmaceutical Design Sex Hormones, Metabolic Syndrome and Kidney
Current Topics in Medicinal Chemistry Multitarget Therapeutic Effect of Fasudil in APP/PS1transgenic Mice
CNS & Neurological Disorders - Drug Targets